GLP-1 Eligibility Checker

What Are GLP-1 Medications and How Do They Work?

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are a class of medications that mimic glucagon-like peptide-1, a hormone naturally produced in the gut after eating. By activating GLP-1 receptors in the pancreas and brain, these drugs slow gastric emptying, reduce appetite, lower blood glucose, and promote satiety — a combination that produces substantial and sustained weight loss in most patients. Research published in the New England Journal of Medicine in 2021 by Dr. Robert Kushner at Northwestern University found that semaglutide 2.4 mg produced an average body weight reduction of 14.9% over 68 weeks — the largest recorded for any non-surgical obesity treatment at the time. Tirzepatide later surpassed this, with 2023 SURMOUNT-1 trial data showing up to 22.5% average weight loss at the highest dose.

GLP-1 Eligibility Requirements: The Full FDA Criteria

GLP-1 eligibility for weight management is governed by FDA approval criteria that are specific to each medication and indication. These eligibility requirements form the basis of every prescribing decision. Understanding them before speaking with a doctor allows for a more focused, productive consultation.

GLP-1 Eligibility Quiz vs. Full Medical Assessment: What Is the Difference?

A GLP-1 eligibility quiz — including this free check — is an educational screening tool that applies published FDA criteria to your self-reported health profile. It identifies whether your BMI, comorbidities, and health history align with the conditions under which these medications are approved. What it cannot do is replace a clinical assessment: it has no access to your actual BMI measurement, blood test results, medication history, or physical examination findings. The purpose of any eligibility test is to give you a well-informed starting point before a medical consultation — not a final answer. A licensed physician, obesity medicine specialist, or telehealth provider remains the only authority on whether a specific GLP-1 prescription is appropriate for you.

GLP-1 Eligibility: NHS Criteria (UK Patients)

GLP-1 eligibility through the NHS differs significantly from FDA criteria and has its own specific requirements that are updated regularly. As of 2025–2026, the NHS has approved semaglutide (Wegovy) for weight management through specialist weight management services under specific conditions: a BMI of 35 or above (or 32.5 or above for certain ethnic groups at higher metabolic risk), at least one weight-related comorbidity, and engagement with a specialist Tier 3 or Tier 4 weight management service. The NHS eligibility pathway is more restrictive than the US FDA criteria and operates through a commissioned two-year programme rather than indefinite prescribing. Availability through the NHS is currently limited due to supply constraints, with many patients accessing semaglutide through private prescribers instead. Private GLP-1 prescriptions in the UK are available through online clinics with BMI criteria typically mirroring FDA thresholds (BMI 30+ or 27+ with comorbidity).

GLP-1 Eligibility in Australia

In Australia, GLP-1 eligibility for weight management follows Therapeutic Goods Administration (TGA) approval pathways. Wegovy (semaglutide 2.4mg) received TGA approval in 2023 for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition — mirroring FDA criteria. However, the medication is not currently listed on the Pharmaceutical Benefits Scheme (PBS) for weight management, meaning patients pay out-of-pocket costs that typically range from AU$350–$450 per month. Ozempic (semaglutide for diabetes) is PBS-listed for type 2 diabetes, which has led to significant supply constraints as off-label weight loss use has compounded prescribing volume. Australian patients considering GLP-1 therapy for weight management typically access it through private prescriptions from GPs or obesity specialists.

GLP-1 Eligibility in the UK (Private Prescriptions)

Beyond NHS criteria, GLP-1 eligibility in the UK through private providers is generally based on FDA-equivalent criteria: BMI of 30 or above, or BMI of 27 or above with at least one qualifying weight-related condition. UK private telehealth providers including Boots, Superdrug Health Clinics, and several specialist online obesity services now prescribe semaglutide and tirzepatide directly following online consultations. Private prescription costs in the UK typically range from £150–£250 per month depending on the provider and medication. The MHRA (UK medicines regulator) has issued guidance on ensuring appropriate clinical assessment prior to prescribing — including blood pressure measurement, medical history review, and contraindication screening.

GLP-1 Eligible for FSA and HSA: What You Need to Know

As of 2025–2026, GLP-1 medications prescribed specifically for type 2 diabetes management (Ozempic, Mounjaro, Rybelsus) are FSA (Flexible Spending Account) and HSA (Health Savings Account) eligible because they are prescription medications treating a diagnosed medical condition. The eligibility status of GLP-1 medications prescribed for weight management (Wegovy, Zepbound) has been less clear, but the IRS has increasingly recognised obesity treatment as a qualified medical expense. A 2023 IRS ruling clarified that prescription medications for obesity treatment are FSA/HSA eligible. Patients should obtain a Letter of Medical Necessity (LMN) from their prescribing physician documenting the medical need for the medication to ensure FSA/HSA reimbursement without issue. Always verify current eligibility with your FSA/HSA plan administrator, as rules can vary by plan.

GLP-1 Eligibility Calculator: How BMI Interacts With Comorbidities

A GLP-1 eligibility calculator essentially performs the same function as a prescriber’s initial assessment — mapping your BMI against the FDA’s two eligibility thresholds. The first threshold is straightforward: a BMI of 30 or above qualifies you for weight management GLP-1 prescriptions regardless of whether you have any additional health conditions. The second threshold is conditional: a BMI between 27 and 29.9 qualifies you only if accompanied by at least one weight-related health condition from the approved list. Our free check models both thresholds and identifies whether your reported BMI range, in combination with your reported conditions, places you within the eligible population. A 2022 analysis by researchers at the University of Alabama published in Obesity Reviews found that approximately 61% of US adults with a BMI between 27–30 have at least one qualifying comorbidity — making the conditional pathway far more widely applicable than most patients realise.

What Counts as a Weight-Related Health Condition?

The FDA-recognised weight-related health conditions that qualify a patient with BMI 27–29.9 for GLP-1 weight management prescriptions are: type 2 diabetes or prediabetes, hypertension (high blood pressure), dyslipidemia (high cholesterol or high triglycerides), obstructive sleep apnea, and established cardiovascular disease (history of heart attack, stroke, or coronary artery disease). Conditions such as osteoarthritis, polycystic ovary syndrome (PCOS), and non-alcoholic fatty liver disease are recognised by many clinical obesity societies as weight-related conditions but are not currently listed in FDA approved labelling as qualifying criteria for the BMI 27+ pathway. Individual prescribers may exercise clinical judgment in borderline cases, making the physician consultation essential for patients near the threshold.

GLP-1 Eligibility Test: Contraindications You Must Know Before Prescribing

Passing a GLP-1 eligibility test based on BMI and comorbidities is necessary but not sufficient — contraindications must be ruled out. The FDA mandates a black box warning on all semaglutide and tirzepatide products regarding a potential risk of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN2). Animal studies demonstrated dose-dependent thyroid C-cell tumours with GLP-1 agonists, and while causality in humans has not been established, the FDA requires prescribers to rule out personal or family history of MTC or MEN2 before prescribing. Additional absolute contraindications include current pregnancy and breastfeeding. Relative contraindications requiring careful clinical judgement include history of pancreatitis, severe gastrointestinal motility disorders, and certain kidney function impairments. Patients on insulin or insulin secretagogues face an increased risk of hypoglycaemia when adding GLP-1 agents and require dose adjustments.

The Difference Between Ozempic, Wegovy, Mounjaro, and Zepbound

The four most commonly prescribed GLP-1 medications in 2025–2026 are frequently confused because two pairs share active ingredients. Ozempic and Wegovy both contain semaglutide — a GLP-1 receptor agonist manufactured by Novo Nordisk. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy uses the same molecule at a higher dose (2.4 mg weekly) and is approved specifically for chronic weight management. Mounjaro and Zepbound both contain tirzepatide — a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management. Tirzepatide’s dual mechanism produces greater average weight loss than semaglutide-only agents, which accounts for the higher average weight loss figures seen in SURMOUNT-1 (tirzepatide, up to 22.5%) compared to STEP-1 (semaglutide, 14.9%). Dr. Ania Jastreboff at Yale and Dr. Louis Aronne at Weill Cornell have both noted in peer-reviewed commentary that the distinction between molecules matters clinically, not just commercially — particularly for patients who do not respond adequately to one agent.

GLP-1 Cost, Insurance Coverage, and Affordability

Cost is one of the most significant practical barriers to GLP-1 access. The list price of Wegovy in the United States is approximately $1,350 per month without insurance (as of 2026). Zepbound carries a similar list price. Insurance coverage has expanded significantly since 2023 but remains inconsistent: GLP-1 medications for type 2 diabetes (Ozempic, Mounjaro) are broadly covered when a diabetes diagnosis is documented. Coverage for the weight management indications (Wegovy, Zepbound) varies widely by plan — many commercial insurers now cover them, but coverage often requires prior authorisation, documentation of prior weight loss attempts, and BMI thresholds above FDA criteria. Medicare Part D began covering Wegovy in 2024 specifically for cardiovascular risk reduction in patients with established CVD and obesity, following the SELECT trial results. Manufacturer patient assistance programs — including Novo Nordisk’s NovoCare and Eli Lilly’s Lilly Cares — provide free or reduced-cost medications to eligible uninsured or underinsured patients. Compounded semaglutide from 503B outsourcing facilities was available as a lower-cost alternative during drug shortages, though regulatory status of compounded GLP-1s has been subject to ongoing FDA enforcement actions in 2025–2026.

Natural Alternatives for People Who Do Not Qualify or Cannot Access GLP-1s

For people who do not meet GLP-1 eligibility criteria, cannot afford the medication, or prefer a non-prescription approach, evidence supports several natural metabolic interventions. Dietary modification — particularly reducing refined carbohydrates, increasing protein, and adopting a Mediterranean-style eating pattern — produces 5–10% weight loss in motivated patients with sustained adherence. Resistance training combined with aerobic exercise addresses both metabolic rate and body composition. Specific supplement ingredients including berberine, green tea extract, and certain probiotic strains have shown modest effects on metabolic markers in controlled trials. Research from the International Journal of Obesity (2019) supports the role of specific Lactobacillus and Bifidobacterium strains in reducing visceral fat through gut microbiome modulation. While no natural supplement replicates the magnitude of GLP-1 drug effects, early-stage metabolic intervention reduces long-term cardiovascular and diabetes risk regardless of whether prescription treatment is pursued.